
Bionique & Cellipont Partner on Rapid Mycoplasma Testing
Key highlights
- Strategic alliance to implement validated rapid mycoplasma detection.
- Supports faster batch release and cGMP compliance.
- Addresses complexity in advanced therapy manufacturing.
- Backed by Bionique's specialized testing expertise.
Notable Quotes
“ This partnership with Cellipont Bioservices represents an exciting opportunity for Bionique to support the advancement of cutting-edge cell therapies. ”
Gladis Zamparo, CEO at Bionique Testing Laboratories
“ Bionique is the gold standard when it comes to mycoplasma testing. ”
Darren Head, CEO at Cellipont Bioservices
Why This Matters
As cell and gene therapies become increasingly vital in modern medicine, ensuring swift and compliant quality control processes is crucial. This partnership allows Cellipont to enhance its testing capabilities by integrating Bionique's rapid mycoplasma detection methods, thereby reducing time-to-release and bolstering regulatory confidence. The collaboration exemplifies the industry's shift towards innovation-driven partnerships to meet the rigorous demands of next-generation therapeutic manufacturing.